Skip to main content

Abstract

Objective:

Early intervention programs are designed to address the needs of youths experiencing first-episode psychosis (FEP). Washington State developed New Journeys, a network of coordinated specialty care programs for FEP. In this study, the authors have outlined components of the New Journeys model and preliminary findings since its initial implementation.

Methods:

Youths and young adults diagnosed as having psychosis (N=112) completed measures at and after intake on a range of mental health assessments and functional outcomes for the first 12 months of treatment. Administrative data including state-funded emergency department and psychiatric hospitalizations were assessed 24 months before and after intake. Generalized estimating equations were used to assess change over time on multiple measures of mental health status.

Results:

Compared with their condition at intake, clients had significant decreases in symptoms of anxiety (β=−2.48, p<0.001), psychotic experiences (β=−3.37, p<0.05), and clinician-rated psychotic symptoms (β=−1.47, p<0.05) during treatment. Additionally, quality of life (β=−5.95, p<0.001) and school attendance (odds ratio=1.42, p<0.05) significantly improved during treatment. Administrative data indicated that postintake, clients were less likely to visit the emergency department for psychiatric reasons (β=0.22, p<0.05), utilize community psychiatric inpatient services (β=0.31, p<0.001), and utilize public assistance (β=0.71, p<0.05) compared with 24 months before intake.

Conclusions:

New Journeys clients experienced improved clinical and functional outcomes during their first year of treatment, and rates of state-funded service utilization decreased during their treatment.

HIGHLIGHTS

The New Journeys program serves as a real-world rollout of a coordinated specialty care program for first-episode psychosis in Washington State.
Findings illustrate the potential impact of New Journeys on clinical and functional outcomes as well as the utilization of state-funded services.
Additional components in early intervention models for first-episode psychosis are needed that focus on substance use.
Individuals diagnosed as having schizophrenia have a life expectancy approximately 30 years shorter than the general population (1, 2). In the United States, an estimated 114,000 new presentations of psychosis occur annually (3). Roughly 75% of individuals with psychotic disorders experience their first-episode psychosis (FEP) before age 25 (4). Treatment of FEP initiated within the critical period following initial onset may improve short- and long-term outcomes for schizophrenia spectrum disorders (5, 6).
Because of successes found in early intervention FEP programs (7), the Substance Abuse and Mental Health Services Administration allocates 10% of the Community Mental Health Services State Block Grant toward the implementation of programs that address FEP. Using these appropriated state funds, Washington State Health Care Authority implemented in 2014 the New Journeys early intervention program for FEP. The model is based primarily on NAVIGATE (7). Approximately 13 states within the United States have since developed early intervention programs based on the NAVIGATE model, but to our knowledge, published data on the outcomes of these programs have been limited.
The aim of this article is to provide an overview and preliminary outcomes of Washington State’s New Journeys network for FEP through an examination of the initial changes in psychiatric symptoms, quality of life, educational and vocational functioning, and substance use for clients during the first 12 months of treatment.

Methods

New Journeys Intervention Model

The New Journeys treatment model includes individualized medication management, family psychoeducation, individual resiliency training, and supported employment and education components of NAVIGATE (8, 9). Individualized medication management focuses on a shared decision-making approach to reduce symptoms and prevent relapses while managing side effects. The goal of individual family psychoeducation is to teach families about psychosis and its treatment while reducing family stress through communication and problem-solving skills.
Individual resiliency training is an individually delivered psychotherapeutic intervention based on positive psychology, illness self-management, and cognitive-behavioral therapy. It focuses on helping clients achieve their personal goals and develop resiliency and skills to target ongoing challenges. Supported employment and education are evidence-based models that support clients in developing and achieving employment and education goals related to their career interests (10). All components of the New Journeys intervention are delivered in person. On the basis of client and family needs, clinicians determine whether family psychoeducation, individual resiliency training, and supported education and employment are delivered on site, within the home, or in the community. Each site utilizes a team-based approach facilitated by weekly meetings to coordinate treatment planning and engagement for each client. To serve a maximum of 30 clients, each team consists of one psychiatrist or advanced registered nurse practitioner (0.2 full-time equivalent [FTE]) and bachelor’s- or master’s-level mental health professionals in the following roles: program director or family education specialist (1.0 FTE), individual resiliency training clinician (1.0 FTE), supported employment and education specialist (1.0 FTE), and case manager (0.5 FTE). A peer specialist role (0.5 FTE) was added to the New Journeys model after the initial implementation period.
Consistent with the elements of a learning health system, and to increase the efficiency of data collection from clients, the implementation and evaluation team along with program developers, clinicians, and administrators modified and developed an existing Web-based dashboard (Toolkit) that would provide both data infrastructure and support a clinical feedback system. Before the implementation of New Journeys, clinicians and administrators provided feedback on the usability and acceptability of the Toolkit prototype, which was used to improve the Toolkit prior to implementation. The Toolkit facilitates the implementation, training, and supervision of evidence-based treatments, and it is accessible by log-in only.

New Journeys Sites

Each year, Washington State distributes a request for information for FEP sites, using funds from the Community Mental Health Services State Block Grant, to all behavioral health organizations and managed care entities in the state. Interested community-based sites are required to apply in response to the request for information. Applications are assessed on population need, experience, community and clinical resources, agency capacity, and sustainability. Determinations are based on the best fit for providing services. Through this mechanism, New Journeys has been implemented sequentially across five counties throughout Washington State. The evaluation team had no direct contact with program clients. The Washington State Institutional Review Board determined that this program evaluation was not human subjects research.

Participants

Between October 15, 2015, and December 31, 2018, a total of 201 potential clients were referred to five clinical sites, of which 112 clients were eligible after screening. Program eligibility included clients ages 15–40; a primary diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or other specified psychotic disorder, as assessed by the Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV; 11); and presence of psychotic symptoms for greater than 1 week and less than 2 years and less than 6 months of treatment with antipsychotic medications. In 2018, a diagnosis of delusional disorder was added to the primary diagnosis inclusion criteria. All insurance types are accepted, and clients who are uninsured are also eligible to receive services. Exclusion criteria included psychosis due to substance intoxication or withdrawal or known to be the result of a medical condition, and more than one episode of psychosis (i.e., a psychotic episode that was followed by full symptom remission and then relapse to another episode).

Training Procedures

During the first 2 years, New Journeys team members participated in yearly in-person training conducted by NAVIGATE treatment developers and the implementation team. Trainers conducted a 2-day workshop that included large group presentations on current and past treatment practices and breakout sessions on specialty roles (i.e., program director, family clinician, individual resiliency training clinician, supported employment and education specialist, and prescribers) and corresponding treatment components, which consisted of demonstrations and behavioral rehearsals. In addition to the NAVIGATE training, team members participated in a 2-day SCID-5-CV training course conducted by a certified SCID trainer. New Journeys team members also participated in a 1-day of training that provided an overview of the Toolkit, information on clinical and functional measures, and an interpretation of results conducted by two members of the evaluation team. Training involved role play, mock data entry, and didactics. To address the training needs of new staff because of turnover, program directors conduct orientations to New Journeys training. Subsequently, the implementation and evaluation team coordinates with program directors to schedule role-specific measurement and data input training.

Ongoing Supervision

Two separate universities hold contracts with the state to provide implementation and evaluation, respectively. In year 1, sites participated in biweekly (for the first 6 months) and monthly phone-based consultations conducted by the NAVIGATE treatment developers. The implementation and evaluation teams provided continuous technical assistance and data monitoring. New Journeys site directors participated in individual monthly calls focused on missing data, site performance reports, barriers to data collection, and staff turnover.

Assessments

The Toolkit provided the online data management support for all sites. The evaluation team selected reliable and valid measures that captured areas of assessment in previous literature, provided meaningful clinical cut-points, were brief, and were at no cost to New Journeys sites (12, 13). The measures selected were a mixture of self-reported and clinician-rated instruments to reduce the burden associated with collecting data. Self-reported measures were completed during appointment times, either directly by the client or delivered by trained providers at the request of the client. Demographic information, psychiatric symptoms, information on real-world functioning, and medical history were collected at intake by site staff.

Psychiatric symptoms.

The eight-item DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) measure was administered separately to the client at intake and weekly during treatment by the individual resiliency training specialist to assess symptom severity across seven domains: hallucinations, delusions, disorganized speech, abnormal psychomotor behavior, negative symptoms, depression, and mania (14, 15). The impaired cognition domain was omitted, which is consistent with the eligibility and exclusion criteria. The CRDPSS is rated on a 5-point Likert scale for each of the seven domains with a maximum score of 28, with higher scores indicative of more severe clinician-rated symptoms of psychosis (16).
The 15-item Community Assessment of Psychic Experiences-Positive (CAPE-P15) scale is a self-report measure with a Cronbach’s α of 0.79 designed to assess the severity of psychosis-like experiences (17). This measure was rated on a 4-point Likert scale with a maximum score of 45 in which higher scores represented more severe psychosis-like experiences (18). The individual resiliency training specialist administered the CAPE-P15 at intake and monthly during treatment.
The nine-question Patient Health Questionnaire (PHQ-9) is a self-report measure with a Cronbach’s α of 0.89 and was administered by the prescriber monthly (19). On a 4-point Likert scale, total scores range from 0 to 27, with higher scores representing more severe depression (20).
The seven-item Generalized Anxiety Disorder (GAD-7) self-report measure is rated on a 4-point Likert scale administered at intake and monthly during treatment with the prescriber and was used to assess symptoms of anxiety, with a Cronbach’s α between 0.79 and 0.91 (21). Total scores range from 0 to 21, with higher scores representing more severe anxiety.

Quality of life.

Questions from the Centers for Disease Control and Prevention’s Health-Related Quality of Life, Healthy Days Core Module were administered at intake and monthly during treatment to evaluate perceptions of overall physical and mental health (2224). For instance, clients were asked, “During the past 30 days, for about how many days did poor physical or mental health keep you from doing your usual activities, such as self-care, work, or recreation?” Responses with more days indicated poorer physical and mental well-being.

Educational status and vocational functioning.

Educational status was determined at intake and was reassessed monthly by the supported employment and education specialist on the basis of the client’s response to the question, “Are you currently enrolled in school?” Employment status was determined at intake and was reassessed monthly during treatment on the basis of the client’s response to the question, “Have you attended work or volunteered 20 or more hours per week in the last month?”

Substance use.

The Car-Relax-Alone-Forget-Family and Friends-Trouble (CRAFFT) measure was modified to include tobacco use and was administered at intake and reassessed monthly by the individual resiliency training specialist (25). This six-item measure, with a Cronbach’s α between 0.68 and 0.86 (26), was used to assess alcohol, drug, and tobacco use in the form of a yes or no question (e.g., “During the past 30 days, did you drink any alcohol [more than a few sips]?”). Affirmative response to two or more questions indicates risk.

Service utilization.

A service utilization measure assessing client attendance at individual components was obtained weekly by New Journeys staff.

Administrative Data

To examine differences in service utilization among New Journeys clients 24 months before and up to 24 months after intake, we obtained data using the Integrated Client Database, which contains individual-level administrative data from multiple state agencies on client service risks, history, and outcomes (27). The 24-month window was selected to match the maximum timeframe of services clients could receive. Prescribed medications, emergency room (ER) visits, inpatient hospitalizations from three different facilities (i.e., medical hospitals, community psychiatric programs, state-funded psychiatric programs), and the use of behavioral health organization mental health services were assessed for only New Journeys participants with Medicaid claims and encounters. Administrative data were used to identify clients who had any services from Washington State’s Economic Services Administration, which includes Temporary Assistance for Needy Families, Basic Food, and other public assistance programs (e.g., Diversion Cash Assistance, Supplemental Security Income–State, Disability Lifeline Unemployment). Administrative data from different sources have varying lengths of delay, and clients admitted into the program after the latest data update were excluded from the analysis. As a result, the final sample sizes for these measures differ by data source.

Statistical Analysis

Descriptive analyses of demographic variables were conducted. Separate generalized estimating equations (GEEs) were used to assess all measures at baseline compared with the first 12 months of treatment. Twelve months was chosen as the cutoff point to maximize the number of available pairs used in GEE and to reduce the effect of missing data. For example, in measuring PHQ-9 scores, 83 clients (74%) were eligible for analysis when we used the 12-month window, which was consistent across measures. GEEs were also used to assess administrative data obtained from Medicaid-eligible participants 24 months preintake and up to 24 months postintake. Administrative data were retrieved for publicly insured eligible clients from four New Journeys sites (N=84). One site was omitted because of its brevity in the New Journeys network, and an additional seven clients were missing intake dates and were excluded from analyses. Given the various intake dates and lengths of treatment among clients, those who had an intake date after the reporting period for each agency were also excluded. Unstandardized regression coefficients and 95% confidence intervals (CIs) are presented for continuous outcomes. Analyses were performed with SPSS, version 25.0, and statistical significance was set at p<0.05.

Results

Client Characteristics

Demographic and clinical characteristics for the 112 clients eligible for New Journeys are presented in Table 1. Of the eligible clients, 90 clients (80%) were actively (one or more services monthly) receiving services as of December 2018, and the mean±SD duration in the program was 10.62±8.58 months. Of the remaining clients not receiving services, 12% (N=13) discontinued services after 8.10±8.50 months, and 8% (N=9) successfully graduated or completed after 9.88±9.76 months.
TABLE 1. Demographic and clinical characteristics of 112 New Journeys clients between 2015 and 2018 in Washington State
CharacteristicN%
Age (M±SD)20.27±3.56 
Gender (male)8476
Race  
 White5246
 Black or African American1110
 Alaska Native44
 Asian44
 Multiracial22
 Other3935
Hispanic3834
Lesbian, gay, bisexual, or questioning1615
Living situation  
 Stable9484
 Temporary1110
 Homeless22
 Other (institutionalized or unstable)33
 Missing22
Primary SCID diagnosisa  
 Schizophrenia3834
 Psychosis not otherwise specified2522
 Schizoaffective disorder1413
 Schizophreniform disorder1917
 Other (PTSD, bipolar 1 disorder)1211
 Missing44
Clinical characteristics (M±SD)  
 Duration of untreated psychosis (days)97.29±167.90b 
 Age at first contact with mental health system17.70±5.80 
 Number of previous psychiatric hospitalizations1.23±1.02 
 Psychosis-like experiences score (CAPE-P15)c8.88±8.67 
 Psychotic symptom severity score (CRDPSS)d10.54±4.91 
 Depression severity (PHQ-9)e6.41±6.54 
 Anxiety severity (GAD-7)f7.36±5.88 
Suicidal thinking in the past 2 weeks1715
Substance use in past 30 daysg  
 Alcohol use10/3330
 Tobacco use (smoking)13/3438
 Cannabis use10/3330
 Other drug use1/343
Health care insurance  
 Public insurance7567
 Private insurance1917
 Uninsured33
 Missing1513
a
SCID, Structured Clinical Interview for DSM-5.
b
Median=12.
c
Possible scores on the 15-item Community Assessment of Psychic Experiences–Positive (CAPE-P15) scale range from 0 to 28, with higher scores indicating greater psychosis symptom severity.
d
Possible scores on the eight-item Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) measure range from 0 to 35, with higher scores indicating greater psychosis symptom severity.
e
Possible scores on the nine-question Patient Health Questionnaire (PHQ-9) range from 0 to 27, with higher scores indicating greater depression symptom severity.
f
Possible scores on the seven-item Generalized Anxiety Disorder (GAD-7) measure range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
g
The numerator refers to the number of clients who reported “yes” to use, and the denominator refers to number of clients who completed the specific question on the Car-Relax-Alone-Forget-Family and Friends-Trouble (CRAFFT) measure.

Clinical and Functional Outcomes

Preliminary analyses on clinical outcomes found significant decreases (or improvements) on the CRDPSS (N=90; β=−1.47, 95% CI=−2.47 to −0.46, p<0.05), CAPE-P15 (N=82; β=−3.37, 95% CI=−4.89 to −1.84, p<0.05), GAD-7 (N=87; β=−2.48, 95% CI=−3.74 to −1.22, p<0.001), and the number of unhealthy days per month (N=84; β=−5.95, 95% CI=−8.85 to −3.05, p<0.001) during the first 12 months of treatment after controlling for site (Figures 1 and 2). There were no significant differences in depression scores assessed by the PHQ-9 or substance use during the first 12 months of treatment. Clients (N=70) were significantly more likely to attend school (odds ratio=1.42, 95% CI=1.02 to 1.96, p<0.05) in the first 12 months of treatment. However, there was no significant change over time for employment.
FIGURE 1. Anxiety, depression, and function outcomes across a 12-month treatment period for 112 New Journeys clients in Washington Statea
aPossible Health-Related Quality of Life, Healthy Days Core Module (HDCM) scores range from 0 to 30 days, with higher days indicating worse health. Possible scores on the seven-item Generalized Anxiety Disorder (GAD-7) measure range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Possible scores on the nine-question Patient Health Questionnaire (PHQ-9) range from 0 to 27, with higher scores indicating greater depression symptom severity. Clinical site was a covariate.
FIGURE 2. Psychosis and psychosis-like experiences across a 12-month treatment period for 112 New Journeys clients in Washington Statea
aPossible scores on the eight-item Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) measure range from 0 to 35, with higher scores indicating greater psychosis severity. Possible scores on the 15-item Community Assessment of Psychic Experiences–Positive (CAPE-P15) scale range from 0 to 28, with higher scores indicating greater psychosis severity. Clinical site was a covariate.

Service Utilization

Of the 112 eligible clients, 18% (N=20) had no data beyond intake, and 82% (N=92) received some services beyond intake. However, an additional 15 clients did not receive any supported employment and education sessions, and nine clients did not attend any individualized medication management sessions. Among family members, 14 did not receive any family psychoeducation (Table 2). Of 92 clients with at least one scheduled appointment beyond intake, clients attended two individual resiliency training sessions (1.84±1.07), one supported employment and education session (1.18±1.06), and one individualized medication management session per month (0.66±0.44), whereas family members attended approximately one family psychoeducation session per month (0.84±0.70).
TABLE 2. New Journeys service utilization of 92 clients in Washington State over 12 monthsa
 Sessions scheduledSessions attended 
Treatment componentSessions (N)Attendees (N)Sessions (N)Attendees (N)Attendance %
Client     
 Individual resiliency training2,215921,6979276.6
 Supported employment and education1,566921,2057776.9
 Medication management920926788373.7
 Family psychoeducation919925817363.2
Family     
 Family psychoeducation919927657883.2
a
92 of 112 clients; 20 clients did not have any data entered after intake. All clients with data attended at least one scheduled session over the period of 12 months.

Administrative Data

Administrative data before and after patients became New Journeys clients are presented in Table 3. The number of clients (N=67) who were prescribed antipsychotic medication (β=1.53, 95% CI=1.17 to 2.00, p<0.05) significantly increased from pre- to postintake. There was a significant decrease in ER visits with a psychiatric diagnosis (β=0.22, 95% CI=0.08 to 0.56, p<0.05) and without a psychiatric diagnosis (β=0.18, 95% CI=0.06 to 0.52, p<0.001) after intake. Client (N=84) utilization of state-funded community psychiatric hospitals (β=0.31, 95% CI=0.16 to 0.60, p<0.001) significantly decreased from pre- to postintake. In addition, client (N=84) utilization of public assistance significantly decreased (β=0.71, 95% CI=0.57 to 0.88, p<0.05) after participating in New Journeys.
TABLE 3. Administrative data of New Journeys clients in Washington State 24 months preintake and up to 24 months postintake
  PreintakePostintake
VariableTotal NN%N%
Behavioral health outpatient servicesa84    
 Any outpatient service used 66796881
Psychiatric emergency room visitsb67    
 One or more 324869
Nonpsychiatric emergency room visitsb67    
 One or more 314658
Inpatient medical hospitalizationsb675769
Community psychiatric inpatient servicesa842631810
State psychiatric inpatient servicesa84    
 Children’s long-term inpatient program 2211
 State psychiatric hospital 5622
Psychotropic medicationb67    
 Antianxiety 15221522
 Antidepressant 22332842
 Antimania 2369
 Antipsychotic 30454669
 ADHD 6935
Public assistancea8452623744
a
Last updated September 2018.
b
Last updated March 2018.

Discussion

New Journeys serves as an example of a state-funded early intervention program for FEP within community-based mental health clinics, in which 54% (N=60) of clients were from racial-ethnic minority groups. More specifically, 34% (N=38) of clients identified as Hispanic, a disproportionately large number relative to the Hispanic population in Washington State (13%; 28). Despite the lack of control group, these preliminary findings demonstrate the potential impact of New Journeys on psychotic symptoms, psychosis-like experiences, and quality of life in the first 12 months of treatment. Together with the recently published outcomes from OnTrackNY (29), these findings highlight the viability of the real-world implementation of an early intervention program and client outcomes during treatment in the United States.
Although previous studies have observed various rates of client enrollment in federal disability benefits (i.e., Supplemental Security Income, Social Security Disability Insurance; 29, 30), New Journeys assessed only receipt of state-funded public assistance. Clients significantly reduced the use of public assistance programs, which possibly demonstrates the impact of early intervention services on the receipt of state benefits. A plausible explanation for the decrease in public assistance may be due to a significant increase in school enrollment, which may affect eligibility for public assistance programs such as Basic Food. Rates of inpatient hospitalizations at medical facilities and state-funded psychiatric facilities were relatively low among clients, and no significant reductions were observed. However, from pre- to postintake, the utilization of community psychiatric inpatient hospitalizations decreased by 20% and ER visits decreased by approximately 40% among New Journeys clients. These findings were lower than the 60% decrease in hospitalizations reported after client enrollment in OnTrackNY (29).
The disengagement rate observed in New Journeys (29.4%) was similar to the 30% rate of disengagement observed in a review of FEP programs (31, 32). In an effort to reduce client and family disengagement, the state will incorporate additional engagement strategies and outreach activities into the New Journeys model, such as expanding the role of the peer support specialist to all sites. Substance use among New Journeys clients did not decrease in their first year of treatment. These findings are consistent with previous research, which found no significant changes in substance use in NAVIGATE (33, 34). Previous research has found that substance use among those with FEP is negatively associated with treatment outcomes (3436), further emphasizing the importance of incorporating effective substance use treatments into early intervention programs.
Several limitations should be considered when interpreting these findings. First, these preliminary findings are limited by the absence of a control condition, making it difficult to draw inferences about the impact of the New Journeys model on client outcomes. Future efforts are aimed to identify a matched comparison using administrative data that will serve as a comparison group to determine the specific impact of New Journeys compared with standard care. Second, the fidelity of treatment delivery was not formally assessed because of evaluation constraints; thus, providers may or may not have delivered treatment components as intended, and the effect this had on treatment outcomes is unknown. However, informal fidelity review during monthly consultation calls was conducted. Third, there was ambiguity in the definition of completed or graduated for the nine clients who were reported as completed. Moving forward, treatment completion needs to be further defined and include clear thresholds for improvement in symptomology that is consistent across sites. Finally, the length of the program and the number of services utilized were not included in the model as potential treatment moderators. As clients continue to complete the New Journeys program, potential moderators such as these should be examined to determine whether the outcomes during and after treatment are sustained and to inform best practices among sites.

Conclusions

Enhancing early interventions for youths and young adults experiencing psychosis is a priority mission for Washington State. On the basis of the initial successes of New Journeys in addressing psychiatric symptoms and functional recovery, recent legislature has been passed promoting the rapid expansion of New Journeys in Washington State. As more community mental health clinics adopt early intervention programs for FEP, additional efforts focusing on substance use behaviors, general health, peer engagement, and measurement-based care are needed. The use of technology-based monitoring systems should also be leveraged to facilitate engagement during and after care. Continually evaluating the effectiveness of the New Journeys program in improving both clinical outcomes and quality of life for individuals with FEP will be crucial as the program continues to expand to new communities within Washington State.

References

1.
Laursen TM, Munk-Olsen T, Vestergaard M: Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25:83–88
2.
Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72:1172–1181
3.
Simon GE, Coleman KJ, Yarborough BJH, et al: First presentation with psychotic symptoms in a population-based sample. Psychiatr Serv 2017; 68:456–461
4.
Van der Gaag M, Nieman D, Van den Berg D: CBT for Those at Risk of a First Episode Psychosis: Evidence-Based Psychotherapy for People With an “At Risk Mental State”. New York, Routledge, 2013
5.
Birchwood M, Todd P, Jackson C: Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl 1998; 172:53–59
6.
Santesteban-Echarri O, Paino M, Rice S, et al: Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev 2017; 58:59–75
7.
Kane JM, Robinson DG, Schooler NR, et al: Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 2016; 173:362–372
8.
Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv 2015; 66:680–690
9.
Robinson DG, Schooler NR, Correll CU, et al: Psychopharmacological treatment in the RAISE-ETP study: outcomes of a manual and computer decision support system based intervention. Am J Psychiatry 2018; 175:169–179
10.
Drake RE, Bond GR: Supported employment: 1998 to 2008. Psychiatr Rehabil J 2008; 31:274–276
11.
First MB, Williams JB, Karg R, et al: Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA, American Psychiatric Publishing, 2015
12.
Uzenoff SR, Penn DL, Graham KA, et al: Evaluation of a multi-element treatment center for early psychosis in the United States. Soc Psychiatry Psychiatr Epidemiol 2012; 47:1607–1615
13.
Kane JM, Schooler NR, Marcy P, et al: The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry 2015; 76:240–246
14.
Barch DM, Bustillo J, Gaebel W, et al: Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res 2013; 150:15–20
15.
Park SC, Lee KU, Choi J: Factor structure of the clinician-rated dimensions of psychosis symptom severity in patients with schizophrenia. Psychiatry Investig 2016; 13:253–254
16.
Arciniegas DB: Psychosis. Continuum 2015; 21:715–736
17.
Capra C, Kavanagh DJ, Hides L, et al: Brief screening for psychosis-like experiences. Schizophr Res 2013; 149:104–107
18.
Núñez D, Arias V, Vogel E, et al: Internal structure of the Community Assessment of Psychic Experiences–Positive (CAPE-P15) scale: evidence for a general factor. Schizophr Res 2015; 165:236–242
19.
Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606–613
20.
Kroenke K, Spitzer RL: The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann 2002; 32:509–515
21.
Spitzer RL, Kroenke K, Williams JB, et al: A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092–1097
22.
Measuring Healthy Days: Population Assessment of Health-Related Quality of Life. Atlanta, Centers for Disease Control and Prevention, 2000
23.
Mielenz T, Jackson E, Currey S, et al: Psychometric properties of the Centers for Disease Control and Prevention Health-Related Quality of Life (CDC HRQOL) items in adults with arthritis. Health Qual Life Outcomes 2006; 4:66
24.
Moriarty DG, Zack MM, Kobau R: The Centers for Disease Control and Prevention’s Healthy Days Measures—population tracking of perceived physical and mental health over time. Health Qual Life Outcomes 2003; 1:37
25.
Knight JR, Sherritt L, Shrier LA, et al: Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med 2002; 156:607–614
26.
Dhalla S, Zumbo BD, Poole G: A review of the psychometric properties of the CRAFFT instrument: 1999–2010. Curr Drug Abuse Rev 2011; 4:57–64
27.
Mancuso D: DSHS Integrated Client Database. Report 11.205. Olympia, Washington State Department of Social and Health Services, Research and Data Analysis Division, Jan 2014
28.
Quick Facts: Washington. Washington, DC: US Census Bureau, 2018. www.census.gov/quickfacts/wa. Accessed Sept 26, 2019
29.
Nossel I, Wall MM, Scodes J, et al: Results of a coordinated specialty care program for early psychosis and predictors of outcomes. Psychiatr Serv 2018; 69:863–870
30.
Rosenheck RA, Estroff SE, Sint K, et al: Incomes and outcomes: Social Security disability benefits in first-episode psychosis. Am J Psychiatry 2017; 174:886–894
31.
Doyle R, Turner N, Fanning F, et al: First-episode psychosis and disengagement from treatment: a systematic review. Psychiatr Serv 2014; 65:603–611
32.
Marino L, Nossel I, Choi JC, et al: The RAISE connection program for early psychosis: secondary outcomes and mediators and moderators of improvement. J Nerv Ment Dis 2015; 203:365–371
33.
Alcover KC, Oluwoye O, Kriegel L, et al: Impact of first episode psychosis treatment on heavy cannabis use: secondary analysis on RAISE-ETP study. Schizophr Res 2019; 211:86–87
34.
Cather C, Brunette MF, Mueser KT, et al: Impact of comprehensive treatment for first episode psychosis on substance use outcomes: a randomized controlled trial. Psychiatry Res 2018; 268:303–311
35.
Oluwoye O, Monroe-DeVita M, Burduli E, et al: Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first-episode psychosis: data from the national RAISE-ETP study. Early Interv Psychiatry 2019; 13:142–146
36.
Breitborde NJ, Bell EK, Dawley D, et al: The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service. BMC Psychiatry 2015; 15:266

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 228 - 235
PubMed: 31847738

History

Received: 17 April 2019
Revision received: 10 September 2019
Accepted: 13 September 2019
Published online: 18 December 2019
Published in print: March 01, 2020

Keywords

  1. Coordinated specialty care
  2. Early intervention
  3. First-episode psychosis
  4. New Journeys

Authors

Details

Oladunni Oluwoye, Ph.D., CHES [email protected]
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Hailey Reneau, B.A.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Bryony Stokes, B.A.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Rebecca Daughtry, M.S.W.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Elizabeth Venuto, M.S.W.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Tenaya Sunbury, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Grace Hong, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Barbara Lucenko, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Bryan Stiles, B.A.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Sterling M. McPherson, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Sarah Kopelovich, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Maria Monroe-DeVita, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).
Michael G. McDonell, Ph.D.
Behavioral Health Innovations (Oluwoye, Reneau, Stokes, McDonell) and Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine (Oluwoye, McPherson, McDonell), Washington State University, Spokane; Youth and Family Behavioral Health Section, Washington State Health Care Authority, Olympia (Daughtry, Venuto); Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia (Sunbury, Hong, Lucenko); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Stiles, Kopelovich, Monroe-DeVita); Providence Medical Research Center, Providence Health Care, Spokane (McPherson).

Notes

Send correspondence to Dr. Oluwoye ([email protected]).
This study was presented in part at the 11th International Conference on Early Intervention in Mental Health, October 7–10, 2018, Boston, and at the 65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 22–27, 2018, Seattle.

Funding Information

This study was supported by National Institute of Mental Health grant K01-MH117457-01A1 and National Institute on Alcohol Abuse and Alcoholism grant R01-AA020248-06. Program implementation and evaluation were funded by Washington State Health Care Authority, Division of Behavioral Health and Recovery, grant 1265-62496.Ms. Venuto contracted with Washington State University to collect data from the New Journeys program for the purpose of annual evaluations to track program outcomes. Dr. McPherson received research funding from the Bristol-Myers Squibb Foundation and the Orthopedic Specialty Institute. Dr. McPherson also consulted for Consistent Care and the U.S. Attorney General’s Office. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share